Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700)

Pharmacology, Toxicology and Pharmaceutical Science

• Ombrabulin 100%
• Neoplasm 60%
• Solid Malignant Neoplasm 40%
• Malignant Neoplasm 40%
• Combretastatin A4 40%
• Anticarcinogen 20%
• Necrosis 20%

Biochemistry, Genetics and Molecular Biology

• Solid 40%
• Combretastatin A-4 40%
• Tumor Blood Flow 40%
• Development 20%
• Exercise 20%
• Experiment 20%

Physics

• Blood Flow 40%
• Solid State 40%
• Tissue 20%
• Therapy 20%